Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol PIRS
Pieris Pharmaceuticals
PIRS
85
$10.09arrow_drop_up0.90%$0.09
High Quality
High Growth
Penny Stock

Performance History

Chart placeholder
Key Stats
Open$9.91
Prev. Close$10.00
EPS-11.4
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap12674305.00
PE Ratio-
LOWHIGH
Day Range9.81
10.58
52 Week Range9.31
76.00
Ratios
P/B Ratio0.64
Revenue-
Operating M. %-10,005.66%
Earnings$0.00
Earnings Growth %26.25%
EBITDA Margin %-9.02%
ROE %-86.86%
EPS-11.4

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Pieris Pharmaceuticals (PIRS)

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stephen S. Yoder J.D.
Headquarters
Boston
Employees
127
Exchange
NASDAQ
add Pieris Pharmaceuticals  to watchlist

Keep an eye on Pieris Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Pieris Pharmaceuticals 's (PIRS) price per share?

The current price per share for Pieris Pharmaceuticals (PIRS) is $10.09. The stock has seen a price change of $0.09 recently, indicating a 0.9% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Pieris Pharmaceuticals (PIRS)?

For Pieris Pharmaceuticals (PIRS), the 52-week high is $76, which is 653.22% from the current price. The 52-week low is $9.31, the current price is 8.38% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Pieris Pharmaceuticals (PIRS) a growth stock?

Pieris Pharmaceuticals (PIRS) has shown an average price growth of 0.41% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Pieris Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Pieris Pharmaceuticals (PIRS) stock price performance year to date (YTD)?

As of the latest data, Pieris Pharmaceuticals (PIRS) has a year-to-date price change of -32.26%. Over the past month, the stock has experienced a price change of -11.26%. Over the last three months, the change has been -25.37%. Over the past six months, the figure is -23.61%. Looking at a longer horizon, the five-year price change stands at -97.1%.

help
Is Pieris Pharmaceuticals (PIRS) a profitable company?

Pieris Pharmaceuticals (PIRS) has a net income of -$24.54M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -10.01K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 65.28%, providing insight into the company's sales performance and growth. The gross profit is $41.03M. Operating income is noted at -$15.84M. Furthermore, the EBITDA is -$13.94M.

help
What is the market capitalization of Pieris Pharmaceuticals (PIRS)?

Pieris Pharmaceuticals (PIRS) has a market capitalization of $12.67M. The average daily trading volume is 4.92K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level